Naringenin, one of the most abundant
flavonoids in citrus, grapefruits and tomatoes, has been used as a traditional
anti-inflammatory agent for centuries. However, the molecular mechanism of
naringenin in intestinal
inflammation remains unknown so far. The present study investigated a molecular basis for the protective effect of
naringenin in
dextran sulphate
sodium-induced murine
colitis. Pre-administration of
naringenin significantly reduced the severity of
colitis and resulted in down-regulation of pro-inflammatory mediators (inducible
NO synthase (iNOS),
intercellular adhesion molecule-1 (ICAM-1),
monocyte chemoattractant protein-1 (MCP-1),
cyclo-oxygenase-2 (Cox2), TNF-α and IL-6
mRNA) in the colon mucosa. The decline in the production of pro-inflammatory
cytokines, specifically TNF-α and
IL-6, correlated with a decrease in mucosal
Toll-like receptor 4 (TLR4)
mRNA and
protein. Phospho-NF-κB p65
protein was significantly decreased, which correlated with a similar decrease in phospho-IκBα
protein. Consistent with the in vivo results,
naringenin exposure blocked
lipopolysaccharide-stimulated nuclear translocation of NF-κB p65 in mouse macrophage RAW264.7 cells. In addition, in vitro NF-κB reporter assays performed on human colonic HT-29 cells exposed to
naringenin demonstrated a significant inhibition of TNF-α-induced NF-κB
luciferase expression. Thus, for the first time, the present study indicates that targeted inhibition of the TLR4/NF-κB signalling pathway might be an important mechanism for
naringenin in abrogating experimental
colitis.